Cardea Bio raises $7.5 million in series A2 financing

Following a $7.8 Million Series A-1 financing announced in March 2019, Cardea, (formerly called Nanomedical Diagnostics), a U.S-based manufacturer of a biology-enabled transistor technology made from graphene-based biosensors, now announced another $7.5 Million raised in the Series A2 Financing.

The capital will help accelerate the growth and development of the Company’s proprietary Tech+Bio Infrastructure and chipsets that enable Cardea’s Innovation Partners to bring “Powered by Cardea" products to market with features and competitive advantages Cardea defines as "never seen before".

Graphenea upgrades its foundry service

Graphenea recently announced that its graphene foundry service (GFAB), launched in 2019, will be getting an upgrade. Graphenea Foundry said that it will start a Multi-Project Wafer run service from January 2021, and it is currently speaking with customers interested in this first run.

Graphenea announces an upgrade to foundry service image

Graphenea Foundry follows a pure-play foundry model, in which it manufactures graphene-based devices for its customers and third parties under request. Nevertheless, the factory also makes usable plug&play graphene devices from scratch, thus covering all aspects of device manufacturing. The staple product and the starting point for satisfying most customer needs is the GFET, the graphene field effect transistor. These readily-available devices are said to be ideal for early experiments and proof-of-concept measurements.

International team reports advances towards tunable graphene plasmonic THz amplifiers

An international team of researchers, led by Tohoku University's professor Taiichi Otsuji, successfully demonstrated a room-temperature coherent amplification of terahertz (THz) radiation in graphene, electrically driven by a dry cell battery.

About 40 years ago, the arrival of plasma wave electronics fascinated scientists with the possibility that plasma waves could propagate faster than electrons, suggesting that so-called "plasmonic" devices could work at THz frequencies. However, experimental attempts to realize such amplifiers or emitters remained elusive.

Graphenea concludes G4SEMI project - integrating graphene into CMOS semiconductor workflows

Graphenea has announced the successful completion of project G4SEMI, funded by the European Commission SME Instrument.

Graphenea completes G4SEMI project image

The project, which lasted two years, aimed at integrating graphene into CMOS semiconductor workflows. The business goal was to create added value through fast-tracking market acceptance of graphene-on-wafer by lowering the technological barriers to adoption of graphene by the €545 billion semiconductor devices industry.

Graphene-based platform could selectively identify deadly strains of bacteria

A team led by Boston College researchers has used a sheet of graphene to track the electronic signals inherent in biological structures, in order to develop a platform to selectively identify deadly strains of bacteria. This effort could lead to more accurate targeting of infections with appropriate antibiotics, according to the team.

Graphene helps create a new platform to selectively ID deadly strains of bacteria image

The prototype demonstrates the first selective, rapid, and inexpensive electrical detection of the pathogenic bacterial species Staphylococcus aureus and antibiotic resistant Acinetobacter baumannii on a single platform, said Boston College Professor of Physics Kenneth Burch, a lead co-author of the paper.